Sibrafiban

Sibrafiban
Identifiers
	IUPAC name [Z]-(S)-[[1-[2-[[4-(amino-hydroxyiminomethyl)-benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxyl]-acetic ethyl ester;
CAS Number	170094-62-9 ;
PubChem CID	5491394;
ChemSpider	4590509;
UNII	YUE443B0NF;
KEGG	D05834;
ChEMBL	ChEMBL435176;
CompTox Dashboard (EPA)	DTXSID90938247 ;
Chemical and physical data
Formula	C20H28N4O6
Molar mass	420.466 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)c2ccc(cc2)C(=N)NO;
	InChI InChI=1S/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1; Key:WBNUCLPUOSXSNJ-ZDUSSCGKSA-N;

Sibrafiban (Ro 48–3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI).^[1] On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients with acute coronary syndrome. The development of sibrafiban was terminated.

References

^ Dooley M, Goa KL (February 1999). "Sibrafiban". Drugs. 57 (2): 225–30, discussion 231–2. doi:10.2165/00003495-199957020-00012. PMID 10188763. S2CID 263996772.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

[pmid10188763-1] Dooley M, Goa KL (February 1999). "Sibrafiban". Drugs. 57 (2): 225–30, discussion 231–2. doi:10.2165/00003495-199957020-00012. PMID 10188763. S2CID 263996772.

[1]

See also

References